Aardvark Therapeutics/$AARD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aardvark Therapeutics
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Ticker
$AARD
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
26
ISIN
US0029421007
Website
AARD Metrics
BasicAdvanced
$235M
-
-$4.40
-
-
Price and volume
Market cap
$235M
52-week high
$13.94
52-week low
$4.88
Average daily volume
36K
Financial strength
Current ratio
25.862
Quick ratio
25.311
Long term debt to equity
0.223
Total debt to equity
0.482
Profitability
EBITDA (TTM)
-31.065
Management effectiveness
Return on equity (TTM)
-34.70%
Valuation
Price to book
1.56
Price to tangible book (TTM)
1.56
Price to free cash flow (TTM)
-2.497
Free cash flow yield (TTM)
-40.05%
Free cash flow per share (TTM)
-434.52%
Growth
Earnings per share change (TTM)
121.84%
AARD News
AllArticlesVideos
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
GlobeNewsWire·4 weeks ago
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewsWire·1 month ago
Aardvark Therapeutics to Present at Upcoming Investor Conferences in May
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aardvark Therapeutics stock?
Aardvark Therapeutics (AARD) has a market cap of $235M as of June 17, 2025.
What is the P/E ratio for Aardvark Therapeutics stock?
The price to earnings (P/E) ratio for Aardvark Therapeutics (AARD) stock is 0 as of June 17, 2025.
Does Aardvark Therapeutics stock pay dividends?
No, Aardvark Therapeutics (AARD) stock does not pay dividends to its shareholders as of June 17, 2025.
When is the next Aardvark Therapeutics dividend payment date?
Aardvark Therapeutics (AARD) stock does not pay dividends to its shareholders.
What is the beta indicator for Aardvark Therapeutics?
Aardvark Therapeutics (AARD) does not currently have a Beta indicator.